EWOC-1: A randomized trial to evaluate the feasibility of three different first-line chemotherapy regimens for vulnerable elderly women with ovarian cancer (OC): A GCIG-ENGOT-GINECO study.



 RE-DEFINIÇÃO DE REPOSTA AO TRATAMENTO ONCOLÓGICO EM MULHERES IDOSAS >70 ANOS MAIS FRÁGEIS COM CÂNCER DE OVÁRIO CONDUZIDA SEM TRES BRAÇOS
-A---CARBO AUC 5/6, TAXOL 3W  PFS =12,5  OS NR ( 21--32--
B---CARBO 3 W SINGLE AGENT  AUC 5/6    PFS=4,3  OS ( 7,4)
C-- CARBO -TAXOL WEEKLY     PFS= 8,3     OS (17,3 MESES )



















Comentários

Postar um comentário

Postagens mais visitadas deste blog

Imagem
 https://sabcs.onlineeventpro.freeman.com/posters/25581279/Efficacy-and-tolerability-of-neoadjuvant-Pertuzumab-Trastuzumab-and-weekly-Paclitaxel-in-Locally-advanced-Her-2-positive-Breast-cancer https://sabcs.onlineeventpro.freeman.com/posters/25582333/Phase-II-pilot-study-of-trastuzumab-biosimilar-herzuma-plus-gedatolisib-in-patients-with-HER-2-positive-metastatic-breast-cancer-who-progressed-after-2-or-more-HER-2-directed https://sabcs.onlineeventpro.freeman.com/posters/25581672/HER2CLIMB-02-A-randomized-double-blind-phase-3-study-of-tucatinib-or-placebo-with-T-DM1-for-unresectable-locally-advanced-or-metastatic-HER2-breast-cancer          
Leia mais